Claudia Wagner, Ph.D.


TCR Discovery & Validation

Claudia Wagner joined Immatics in May 2012 and is responsible for T-cell receptor (TCR) discovery and validation on the XCEPTOR™ platform. In her department, TCRs recognizing proprietary XPRESIDENT® tumor antigens are isolated from blood products of healthy individuals and patients, followed-by extensive characterization in human cells. Suitable candidates for immunotherapy, either for adoptive cell therapy (ACT) or soluble TCR bispecifics, are tested preclinically for efficacy and safety. Additionally, Claudia is responsible for the refolding unit of peptide-MHC complexes at Immatics.

In 2006, Claudia Wagner obtained her immunology-focused PhD at the Center for Infectious Medicine at Karolinska Institutet, Stockholm, Sweden. She was then trained as postdoctoral fellow in the Department of Immunobiology at Yale University, New Haven, USA prior to joining Immatics. Claudia also holds a master’s degree in Biomedicine from the Karolinska Institutet.


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.